OBI vs. SBTX, HEMO, OPTI, OBD, DEST, NSCI, ONC, IMM, SNG, and SAR
Should you be buying Ondine Biomedical stock or one of its competitors? The main competitors of Ondine Biomedical include SkinBioTherapeutics (SBTX), Hemogenyx Pharmaceuticals (HEMO), OptiBiotix Health (OPTI), Oxford BioDynamics (OBD), Destiny Pharma (DEST), NetScientific (NSCI), Oncimmune (ONC), ImmuPharma (IMM), Synairgen (SNG), and Sareum (SAR). These companies are all part of the "biotechnology" industry.
Ondine Biomedical (LON:OBI) and SkinBioTherapeutics (LON:SBTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, community ranking, profitability, media sentiment, earnings, risk and valuation.
SkinBioTherapeutics' return on equity of -126.85% beat Ondine Biomedical's return on equity.
8.9% of Ondine Biomedical shares are held by institutional investors. Comparatively, 12.0% of SkinBioTherapeutics shares are held by institutional investors. 61.5% of Ondine Biomedical shares are held by company insiders. Comparatively, 28.1% of SkinBioTherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Ondine Biomedical has a beta of -0.14, indicating that its share price is 114% less volatile than the S&P 500. Comparatively, SkinBioTherapeutics has a beta of 1.52, indicating that its share price is 52% more volatile than the S&P 500.
In the previous week, Ondine Biomedical and Ondine Biomedical both had 2 articles in the media. Ondine Biomedical's average media sentiment score of 0.36 beat SkinBioTherapeutics' score of 0.09 indicating that Ondine Biomedical is being referred to more favorably in the media.
SkinBioTherapeutics received 46 more outperform votes than Ondine Biomedical when rated by MarketBeat users. However, 100.00% of users gave Ondine Biomedical an outperform vote while only 60.26% of users gave SkinBioTherapeutics an outperform vote.
SkinBioTherapeutics has lower revenue, but higher earnings than Ondine Biomedical. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Ondine Biomedical, indicating that it is currently the more affordable of the two stocks.
Summary
SkinBioTherapeutics beats Ondine Biomedical on 8 of the 13 factors compared between the two stocks.
Get Ondine Biomedical News Delivered to You Automatically
Sign up to receive the latest news and ratings for OBI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OBI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Ondine Biomedical Competitors List
Related Companies and Tools